NICE green light for Roche’s Rozlytrek
The drug targets all solid tumours with the NTRK gene fusions
Read More
Tag: entrectinib
NICE backs Rozlytrek for subset of NSCLC patients
Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originates
Read More
Rozlytrek bags FDA approval
For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
Read More
FDA Priority Review for Roche’s entrectinib in cancer treatment
Roche has announced that the FDA has granted Priority Review for entrectinib as a treatment for NTRK fusion-positive, locally advanced or metastatic solid tumours, and to treat metastatic ROS1-positive non-small-cell lung cancer.
Read More
Roche to file entrectinib for ROS-1 positive NSCLC
Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients with ROS1-positive non-small cell lung cancer (NSCLC).
Read More
Roche to buy Ignyta for $1.7 billion
Roche has announced plans to buy US group Ignyta for $27 a share in an all-cash deal totaling around $1.7 billion, securing itself access to the latter’s experimental cancer medicines.
Read More
PRIME status for Ignyta’s entrectinib
European regulators have awarded Ignyta’s cancer drug entrectinib Priority Medicines (PRIME) designation, potentially placing the treatment on a faster path to approval.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
